Botha Roelof, an insider at Natera Inc (NTRA), sold 1,214,660 shares of the company on November 23, 2025, at a price of $233.66 per share, totaling $283.82 million. Following this transaction, Roelof retains an equal number of shares in Natera.
Natera, a biotechnology company based in Austin, Texas, specializes in genetic testing services. The firm, which went public on July 2, 2015, employs 4,424 full-time staff and has developed a range of innovative products, including non-invasive prenatal testing (Panorama) and individualized cancer care assays (Signatera). The company is also focused on organ health, offering tests for transplant rejection and genetic conditions.
The move underscores the complexities surrounding insider transactions, which can occur for various reasons, including personal financial needs or tax planning. While significant sales may attract investor attention, they do not inherently signal negative sentiment toward the company.
Investors are encouraged to consider broader patterns of insider activity, rather than isolated transactions, when evaluating market signals. Natera currently has a market capitalization of $32.7 billion and an EPS (TTM) of -2.28, with upcoming earnings reports scheduled for May 6, 2026, and August 5, 2026, projecting EPS estimates of -$0.50 and -$0.54, respectively.